Priti Lal, MD
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Tissue Microarray Laboratory, Hospital of the University of Pennsylvania
Staff Pathologist, Hospital of the University of Pennsylvania
Director, Genito-Urinary Pathology Service, Hospital of the University of Pennsylvania
Director, CME series ICC , Hospital of the University of Pennsylvania
Chair, Clinical Curriculum Committee, General Surgpath Fellowship, University of Pennsylvania
Department: Pathology and Laboratory Medicine
Contact information
Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
6 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104-4283
Hospital of the University of Pennsylvania
6 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 2156626503
Publications
Links
Search PubMed for articles
PCF grant
Supported by Dana-Farber Cancer Institute, MADCaP is grant-funded by the National Cancer Institute
Emory Interview for RO1
GU Pathologist and a student forever! Center for Global Health Scholar, Perelman School of Medicine, University of Pennsylvania
June 2023 Citations Report H Index of 33 (Top5%); 5903 Citations and 82 Mentions
Search PubMed for articles
PCF grant
Supported by Dana-Farber Cancer Institute, MADCaP is grant-funded by the National Cancer Institute
Emory Interview for RO1
GU Pathologist and a student forever! Center for Global Health Scholar, Perelman School of Medicine, University of Pennsylvania
June 2023 Citations Report H Index of 33 (Top5%); 5903 Citations and 82 Mentions
Education:
BS (Genetics)
Delhi University, Delhi, India, 1984.
MD
Maulana Azad Medical College, Delhi, India, 1990.
Permanent linkBS (Genetics)
Delhi University, Delhi, India, 1984.
MD
Maulana Azad Medical College, Delhi, India, 1990.
Description of Research Expertise
Application of high through-put technology to gain insights into the biology of human cancers, with focus on urothelial and prostate cancers.Description of Clinical Expertise
GU PathologySelected Publications
Vivek Narayan, Julie S. Barber-Rotenberg, In-Young Jung, Simon F. Lacey, Andrew J. Rech, Megan M. Davis, Wei-Ting Hwang, Priti Lal, Erica L. Carpenter, Shannon L. Maude, Gabriela Plesa, Neha Vapiwala, Anne Chew, Michael Moniak, Ronnie A. Sebro, Michael D. Farwell, Amy Marshall, Joan Gilmore, Lester Lledo, Karen Dengel, Sarah E. Church, Tyler D. Hether, Jun Xu, Mercy Gohil, Thomas H. Buckingham, Stephanie S. Yee, Vanessa E. Gonzalez, Irina Kulikovskaya, Fang Chen, Lifeng Tian, Kyle Tien, Whitney Gladney, Christopher L. Nobles, Hayley E. Raymond, Prostate Cancer Cellular Therapy Program Investigators, Elizabeth O. Hexner, Donald L. Siegel, Frederic D. Bushman, Carl H. June, Joseph A. Fraietta & Naomi B. Haas: PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine 4(28): 724-734, April 2022.Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal Priti, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM: Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol 33(25): 2789-96, September 2015.
Vaughn DJ, Hwang WT, Lal Priti, Rosen MA, Gallagher M, O'Dwyer PJ: Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors. Cancer 121(9): 1463-8, May 2015.
Garg R, Blando JM, Perez CJ, Lal Priti, Feldman MD, Smyth EM, Ricciotti E, Grosser T, Benavides F, Kazanietz MG: COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer. Oncogene 37(34): 4735-4749, August 2018.
Bhargava HK, Leo P, Elliott R, Janowczyk A, Whitney J, Gupta S, Fu P, Yamoah K, Khani F, Robinson BD, Rebbeck TR, Feldman M, Lal Priti, Madabhushi A: Computationally derived image signature of stromal morphology is prognostic of prostate cancer recurrence following prostatectomy in African American patients. Clin Cancer Res 26(8): 1915-1923, April 2020.
Rasool RU, Natesan R, Deng Q, Aras S, Lal Priti, Sander Effron S, Mitchell-Velasquez E, Posimo JM, Carskadon S, Baca SC, Pomerantz MM, Siddiqui J, Schwartz LE, Lee DJ, Palanisamy N, Narla G, Den RB, Freedman ML, Brady DC, Asangani IA: CDK7 inhibition suppresses Castration- Resistant Prostate Cancer through MED1 inactivaion. Cancer Discov 9(11): 1538-1555, November 2019.
Arriola AGP, Farahani SJ, Bhargava HK, Guzzo TJ, Brooks JSJ, Lal Priti: PDL-1 Expression reveals significant association with squamous differentiation in Upper Tract Urothelial Carcinoma. Am J Clin Pathol 151(6): 561-573, February 2019
Sadigh S, Farahani SJ, Shah A, Vaughn D, Lal Priti: Differences in PD-L1 Expressing Macrophages and Immune Micro-environment in Testicular Germ Cell Tumors. Am J Clin Pathol 153(3): 387-395, February 2020.
Vivek Narayan, Whitney Gladney, Gabriela Plesa, Neha Vapiwala, Erica Carpenter, Shannon L. Maude, Priti Lal, Simon F. Lacey, Jan Joseph Melenhorst, Ronnie Sebro, Michael Farwell, Wei-Ting Hwang, Michael Moniak, Joan Gilmore, Lester Lledo, Karen Dengel, Amy Marshall, Christina Marie Coughlin, Carl H. June, Naomi B. Haas: A Phase 1 Clinical Trial of PSMA-directed/TGFβ-insensitive CAR-T cells in Metastatic Castration-Resistant Prostate Cancer. Am Soc of Clin Onc 2020. J of Clin Onc May 2020.
Facciabene A, Peng X, Ian SH , Barchetti A, Balint K, Wang LP, Gilks CB, Lal Priti, Zhang L, Coukos G: Tumor Hypoxia Recruits Regulatory T Cells via the CCL28 Chemokine to Promote Immune Tolerance and Angiogenesis. Nature 475(7355): 226-230, July 2011.